Skip to main content

Catalent Value Stock - Dividend - Research Selection


ISIN: US1488061029, WKN: A112H2

Market price date: 20.01.2022
Market price: 102,02 USD

Catalent Fundamental data and company key figures of the share

Annual reports in USD
Key figures 13-04-2021
Cash flow
Net operating cash flow 440.300.000
Capital Expenditures -465.800.000
Free cash flow -25.500.000
Balance sheet
Total Equity 3.505.400.000
Liabilities & Shareholders equity 7.776.500.000
Income statement
Net income 220.700.000
Eps (diluted) 1,355
Diluted shares outstanding 162.800.000
Net sales/revenue 3.094.300.000

Fundamental ratios calculated on: 20-01-2022

Key figures 20-01-2022
Cash flow
P/C 37,72
P/FC -651,33
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization16.608.856.064,00 USD
CountryUnited States
IndicesS&P 500
Raw Data SourceUS GAAP in Millionen USD
Stock Split

Description of the company

Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has a collaboration with the Janssen Pharmaceutical Companies; Arcturus Therapeutics Holdings Inc.; and BrainStorm Cell Therapeutics Inc. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


BD (BDX) Hits a New 52-Week High: What's Behind the Rally?

Shares of Becton, Dickinson and Company BDX, popularly known as BD, reached a new 52-week high of $268.55 on Jan 20, before closing the session marginally lower at $263.97.

Catalent, Inc. Announces Second Quarter Fiscal Year 2022 Earnings Conference Webcast

Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies, as well as consumer... | January 21, 2022

Nevro's (NVRO) Senza Gets FDA Nod for Expanded Labeling for NSRBP

Nevro Corp. NVRO recently received the FDA’s approval for expanded labeling for its Senza Spinal Cord Stimulation (“SCS”) System associated with the treatment of non-surgical refractory back pain (“NSRBP”). The approval, which is specific to Nevro's exclusive 10 kHz Thera

3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio

Catalent, Inc. CTLT has been gaining on the back of its robust facility expansion activities over the past few months. A robust first-quarter fiscal 2022 performance, along with a slew of strategic deals over the past few months, is expected to contribute further. Catalen

Catalent (CTLT) to Advance Oral Drug Development With New Launch

Catalent, Inc. CTLT recently launched a new Xpress Pharmaceutics service, which aims to further the development of oral drugs through Phase 1 clinical studies. This approach can lower the cost and time needed to complete first-in-human trials by combining formulation deve

Catalent Launches New Xpress Pharmaceutics Service to Expedite Development of Oral Drugs for Adaptive Phase 1 Clinical Trials

SOMERSET, N.J. - Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple... | January 19, 2022

Microsoft's $68.7 billion deal for Activision once again shows big tech's dominance over legacy media

Microsoft takes big $68.7 billion swing on video game company Activision Blizzard while legacy media stays on sidelines

Catalent : Launches New Xpress Pharmaceutics™ Service to Expedite Development of Oral Drugs for Adaptive Phase 1 Clinical Trials

SOMERSET, N.J. - January 18, 2022 - Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch,... | January 18, 2022

PacBio (PACB) Reports Impressive Preliminary Q4, FY21 Revenues

PacBio's (PACB) solid fourth-quarter results are likely to have been boosted by strong segmental performances and robust placement of Sequel systems.

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Launched on 06/23/2005, the Invesco Dynamic Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market.